Numinus Wellness Inc · OTC:NUMIF
Numinus Wellness — Investor Presentation (August 2022)
18 slides from Numinus Wellness's investor presentation, August 2022
Slide 1: Investor Presentation
NUMINUS Investor Presentation A leading, integrated mental health care company providing psychedelic-assisted therapies AUGUST 2022 NUMINUS WELLNESS INC. (TSX: NUMI) (OTCQX: NUMIF)
Slide 2: Forward-Looking Statements
NUMINUS Forward-Looking Statements This presentation includes certain “forward-looking information” and “forward-looking statements" (collectively “forward-looking statements") within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, bel
Slide 3: INVESTOR PRESENTATION
INVESTOR PRESENTATION 3 • • • • • •
Slide 4: Addressing a growing need
NUMINUS INVESTOR PRESENTATION Addressing a growing need MARKET OPPORTUNITY Current systems are not equipped to handle skyrocketing global rates of mental iliness, addiction and trauma, further $538 bil exacerbated by the Covid pandemic. $3 80 b l [+ by 2030 One in four Canadians aged During the pand
Slide 5: An integrated health care model
NUMINUS An integrated health care model WELLNESS CLINICS Network of 13 clinics delivering a comprehensive offering of mental health services for the treatment of depression, mental illness, neurological disorders and related conditions. NUMINUS cedar BY NUMINUS NEUROLOGY ‘CENTRE OF . ‘TORONTO a Mind
Slide 6: INVESTOR PRESENTATION
INVESTOR PRESENTATION 6 6 • • • • • • • • • •
Slide 7: Psychedelic medicine is transforming health care
NUMINUS INVESTOR PRESENTATION a Psychedelic medicine is transforming health care Taken in coordination with therapy from a trained psychotherapist: « Psilocybin may relieve major depression with 4x the efficacy of traditional antidepressants! « MDMA for PTSD shows substantial clinical impact and pot
Slide 8: Acquisition of Novamind
NUMINUS Acquisition of Novamind KEY STRATEGIC BENEFITS 1. Rapidly expanded Numinus’ operations and brand into the U.S. with a reputable platform of revenue producing clinics with an established and growing client base. 2. Combined Novamind’s leading clinical research site management capabilities wit
Slide 9: A growth focused strategy
NUMINUS INVESTOR PRESENTATION A growth focused strategy The recent acquisition of Novamind has significantly increased the number clinics under the Numinus brand, and expanded our operations into the US. A network of clinics delivering treatments for CLINIC GROWTH depression, mental illness, addicti
Slide 10: A Scalable Platform across North America
NUMINUS INVESTOR PRSENTATION. » A Scalable Platform across North America With 18 client wellness clinics operating across North America, as well as 4 clinical research facilities and one research lab, Numinusis a leading provider of psychedelic-assisted therapies with significant opportunities for c
Slide 11: ProForma Financial Highlights
NUMINUS INVESTOR PRESENTATION ProForma Financial Highlights PROFORMA REVENUE $4,500,000 $4.01 mil $4,000,000 $3,500,000 $3.24 mil $3,000,000 $2.31 mil $2.35 mil $2,500,000 . $2,000,000 $1,500,000 $1,000,000 $500,000 $- 3/94 2021 Q4/Q1 2021 1/92 2022 02/93 2022 (May/June) (Aug/Sep) (Nov/Dec) (Feb/Mar
Slide 12: INVESTOR PRESENTATION
INVESTOR PRESENTATION 12 • • • • •
Slide 13: Special Access Programme (SAP)
NUMINUS Pe arseniies fe Special Access Programme (SAP) CANADA On January 5, 2022, Health Canada implemented several important amendments to SAP, providing Canadians with access to Psychedelic therapies in qualified cases. These changes now enable doctors and practitioners to apply for psychedelic me
Slide 14: INVESTOR PRESENTATION
INVESTOR PRESENTATION 14 • • • • • • • • • • • • •
Slide 15: INVESTOR PRESENTATION
INVESTOR PRESENTATION 15 15 • • • • • • • • • • 15
Slide 16: Q2 2022 results
NUMINUS INVESTOR PRESENTATION Results demonstrated the strength of our growing Q 3 y) Q y) y) wellness clinic network and the strategic realignment underway at Numinus Bioscience 31.8% 7.5% 59.1% 24.4% Revenue growth Clinic network Clinic network Gross Margin compared Q3 2021 revenue growth revenue
Slide 17: Building a transformative platform for mental wellness
Building a transformative platform for mental wellness With 13 wellness clinics located across North America, C$12 million of proforma revenue (trailing 4Q), complementary business divisions providing clinical trial management services and psychedelics research, and a well capitalized balance sheet,
Slide 18: Contact
NUMINUS Email: [email protected] Investor website: investors.numinus.com
Numinus Wellness — Investor Presentation (August 2022) on 6ix